AUS
NZ
UK
CA
USA
IND
_07_17_2023_11_54_00_546595.jpg)
BlinkLab Limited (ASX:BB1), a digital healthcare firm specializing in AI-driven diagnostics, has finalized a A$17.5 million placement at A$0.65 per share to support its U.S. FDA 510(k) registration study for the flagship BlinkLab Dx1 autism diagnostic technology. Concurrently, the company announced the issuance of a foundational U.S. patent safeguarding its remote neurobehavioral testing platform until 2041, alongside new international research collaborations and the completion of European ADHD study recruitment. These developments position BlinkLab to enhance its diagnostic and therapy evaluation capabilities across multiple neurodevelopmental disorders.
Key Highlights
- BlinkLab Limited (ASX:BB1) develops AI-powered smartphone-based remote neurobehavioral testing solutions targeting neurodevelopmental disorders such as autism and ADHD.
- The company raised A$17.5 million via placement to sophisticated and institutional investors at A$0.65 per share, funding FDA 510(k) study completion, European regulatory efforts, ADHD program expansion, and commercial readiness.
- On 18 June 2026, BlinkLab was granted a foundational U.S. patent (No. 12,653,444 B2) protecting its remote neurobehavioral testing technology through 2041, under an exclusive global license from Princeton University.
- New research partnerships with Erasmus University Medical Center (Netherlands) and Escuela Superior Politécnica de Chimborazo (ESPOCH, Ecuador) extend BlinkLab’s platform into therapy evaluation and real-world evidence generation across diverse regions.
- European ADHD study recruitment concluded with approximately 375 child participants; data is now ready for analysis, with results expected imminently.
- As of 30 June 2026, BlinkLab’s cash balance stood at approximately A$17.9 million, supporting ongoing clinical development and regulatory activities.
A$17.5 Million Placement Bolsters Financial Capacity for FDA Regulatory Milestones
BlinkLab successfully completed a A$17.5 million placement at A$0.65 per share to sophisticated and institutional investors, raising capital before costs. This funding supports key strategic initiatives including the FDA 510(k) registrational study for BlinkLab Dx1, European regulatory submissions, ADHD program growth, platform enhancements, and commercial preparation. The capital raise is critical to advancing the company’s U.S. regulatory pathway while progressing clinical programs across multiple neurodevelopmental conditions.
The timing aligns with pivotal milestones: the FDA 510(k) pivotal validation program for autism is underway, and ADHD study results are expected shortly. CEO and Co-founder Dr Henk-Jan Boele highlighted that the combination of secured funding, foundational U.S. patent protection, and a strengthened balance sheet positions BlinkLab to effectively execute its regulatory and commercial strategies. The A$17.9 million cash position as of 30 June 2026 reflects the placement proceeds and provides a runway for concurrent clinical and regulatory activities.
Foundational U.S. Patent Provides Long-Term Protection Through 2041
On 18 June 2026, BlinkLab announced the grant of U.S. Patent No. 12,653,444 B2 by the United States Patent and Trademark Office, granting exclusive protection for its core remote neurobehavioral testing technology until 2041. The patent, titled "System and Method for Remote Neurobehavioral Testing," covers systems and methods employing audiovisual stimuli, including conditioned eyeblink responses and prepulse inhibition, foundational to BlinkLab’s diagnostic platform. The technology was developed by co-founders Dr Henk-Jan Boele and Professor Samuel S.H. Wang of Princeton University, with BlinkLab holding an exclusive worldwide license from Princeton.
This patent milestone secures long-term intellectual property rights in the U.S. healthcare market, enhancing BlinkLab’s competitive advantage and market exclusivity. The 15-year protection window from grant is significant in the medical diagnostics sector, supporting the company’s FDA approval and commercialization efforts. The exclusive Princeton license further solidifies BlinkLab’s global commercialization rights.
European ADHD Study Recruitment Finalized with 375 Participants; Data Ready for Analysis
On 26 June 2026, BlinkLab confirmed completion of recruitment and data collection for its European ADHD study, conducted in partnership with Mental Care Group (MCG), a leading European mental health provider. Approximately 375 children participated, and quality-control assessments verified the dataset’s completeness and consistency, now ready for analysis. This marks a major milestone following a 2024 pilot study and supports further development of BlinkLab Dx2, the company’s ADHD-focused technology.
Dr Boele noted that ADHD study results are expected imminently, marking a key inflection point. Positive findings could expand the clinical validation of BlinkLab’s platform beyond autism to additional neurodevelopmental disorders. The study also demonstrates BlinkLab’s capacity to execute large-scale, multi-center clinical research alongside established healthcare organizations.
Erasmus University Medical Center Partnership Advances Therapy Evaluation Capabilities
On 19 May 2026, BlinkLab announced a strategic collaboration with Erasmus University Medical Center in the Netherlands to study treatment-related changes in behavioral and neurodevelopmental function in patients with Activated PI3K Delta Syndrome (APDS), a rare immune disorder linked to neurodevelopmental conditions including autism. The study monitors patients before and during treatment with a selective PI3K-delta inhibitor, a targeted therapy for APDS.
This partnership expands BlinkLab’s platform utility beyond diagnostics into therapy evaluation and digital endpoints for pharmaceutical clinical trials. As targeted therapies for rare genetic disorders grow, pharmaceutical and academic groups require objective, remote, repeatable endpoints. BlinkLab’s sensorimotor neurometric platform meets this need, opening new revenue streams as a digital endpoint provider alongside diagnostic offerings.
Research Collaboration with Ecuador’s ESPOCH Enhances Global Evidence Base
On 16 June 2026, BlinkLab announced a research collaboration with Escuela Superior Politécnica de Chimborazo (ESPOCH) in Ecuador for a multi-center study on autism, sensorimotor function, nutrition, and gut microbiota. The "Proyecto Wiñay" program, funded by ESPOCH under a two-year agreement within a broader five-year framework, involves BlinkLab providing its smartphone-based platform and technical support while retaining ownership of technology and collected data.
This partnership extends BlinkLab’s global research presence into South America, generating real-world evidence from diverse populations and healthcare settings. Retaining data ownership enables further platform development and validation across clinical applications beyond pediatric autism, including nutrition and gut health, areas increasingly linked to neurodevelopmental outcomes. The collaboration also enhances BlinkLab’s academic and clinical profile, supporting commercial and partnership growth.
FDA 510(k) Autism Validation Program Progresses as Planned
Throughout the June Quarter, BlinkLab advanced its U.S. FDA 510(k) pivotal validation study for BlinkLab Dx1 autism technology, establishing a clinical network of leading autism centers and research institutions across the U.S. Participant recruitment and testing have continued since the previous quarter. Dr Boele emphasized that the autism program "continued to progress according to plan during the quarter and remains our clear priority."
The FDA 510(k) pathway is critical for market authorization in the U.S., demonstrating BlinkLab Dx1’s equivalence or superiority to predicate devices in diagnostic accuracy and clinical utility. Successful FDA clearance would unlock significant commercial opportunities in the U.S. healthcare market. Engagement with key opinion leaders and clinical centers supports both validation and future adoption.
Global Investor Engagement and Board Presence at Asia-Pacific Investment Events
During the June Quarter, BlinkLab’s Board and management participated in major investment forums across Australia and the Asia-Pacific region, including Ignite Investment Summits in Singapore and Hong Kong, and the Stocks in the Vines event in Australia. These activities align with the company’s goals of capital raising, partnership development, and regional market expansion.
Engagement in Asia-Pacific supports BlinkLab’s global expansion strategy, complementing FDA and European regulatory efforts. Asia-Pacific markets such as Australia, Singapore, and Hong Kong represent significant opportunities for digital health and pediatric neurodevelopmental diagnostics. The company’s visibility in these markets strengthens long-term strategic positioning amid growing healthcare spending and digital adoption.
Expanding Clinical and Commercial Applications Beyond Pediatric Autism and ADHD
Dr Boele highlighted that BlinkLab’s technology is increasingly applied beyond pediatric autism and ADHD, including adult autism diagnosis, lifestyle monitoring, and rare genetic disorders. Emerging applications encompass treatment response evaluation (evidenced by the Erasmus University APDS study), nutrition and gut health monitoring (via ESPOCH collaboration), and broader neurobehavioral assessments. This diversification creates multiple pathways for clinical evidence generation, regulatory approvals, and commercial growth across a wider spectrum of neurodevelopmental and neurological conditions.
Expanding into adult autism and treatment monitoring opens new market segments beyond pediatric diagnostics. Adult autism remains an unmet need, while digital endpoints for pharmaceutical development are growing opportunities. By addressing diverse clinical domains, BlinkLab broadens its addressable market and reduces reliance on a single indication. The CEO expressed enthusiasm about these applications’ potential to "create additional long-term clinical and commercial opportunities," underscoring confidence in the platform’s broad neurobehavioral measurement capabilities.
Robust Intellectual Property and Regulatory Strategy Supports Long-Term Market Leadership
BlinkLab’s intellectual property approach includes the foundational U.S. patent, exclusive Princeton license, and retention of technology and data ownership across international research collaborations. This strategy protects core technology from competitors and ensures clinical evidence benefits BlinkLab. The patent protection through 2041 offers a substantial exclusivity period for development, validation, and commercialization without direct patent competition.
The regulatory strategy prioritizes FDA 510(k) approval for autism diagnostics while concurrently developing ADHD, therapy evaluation, and other applications through international collaborations. This phased, multi-indication, multi-geography approach mitigates regulatory and commercial risk by diversifying pathways and markets. Collaborations with Erasmus, ESPOCH, and Mental Care Group, alongside FDA clinical networks, provide infrastructure and expertise for scalable validation and submissions. The successful A$17.5 million placement reflects investor confidence in BlinkLab’s strategic positioning and regulatory roadmap.
